Oxford BioMedica Leaves Door Open for Private Equity Takeover

UK-based gene therapy company Oxford BioMedica has rejected multiple unsolicited bids from private equity firm EQT but indicated it remains open to a takeover if the right deal emerges. The company emphasized that any potential acquisition must align strategically and in valuation. After evaluating EQT's proposals, Oxford BioMedica concluded that the current offers do not reflect the company's long-term growth potential. However, management stated they are not entirely closed to future bids and will consider any option that delivers the best value for shareholders. The company continues its strategy of growing as an independent entity, maintaining its leading position in gene therapy and a strong pipeline. Oxford BioMedica remains focused on its current operational targets and notes that any potential deal must align with the company's vision. This is not investment advice.